Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors

R: A language and environment for statistical computing.

2014 • 297,811 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

2016 • 8,644 citations

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

2015 • 8,603 citations

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

2015 • 7,844 citations

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

2006 • 5,595 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

2018 • 5,373 citations

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

2018 • 3,140 citations

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

2018 • 3,046 citations

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

2015 • 1,333 citations

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

2016 • 968 citations

PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

2016 • 434 citations

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

2017 • 412 citations

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer

2017 • 408 citations

Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab

2015 • 235 citations

Immune checkpoint inhibitors in advanced non–small cell lung cancer

2017 • 106 citations

Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer

2016 • 70 citations

Immune-Related Adverse Events: Pneumonitis

2020 • 60 citations

Practical Management of Immune-Related Adverse Events from Immune Checkpoint Protein Antibodies for the Oncologist

2012 • 55 citations

Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?

2019 • 38 citations

MA 09.08 Receipt of Chest Radiation and Immune-Related Pneumonitis in Patients with NSCLC Treated with Anti-PD-1/PD-L1

2017 • 17 citations

A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer

2019 • 3 citations